Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02901899 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

DRUG: Guadecitabine
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]